PledPharma AB (publ) Stock Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
Sales 2024 * | 68.03M 6.39M | Sales 2025 * | 514M 48.32M | Capitalization | 2.08B 196M |
---|---|---|---|---|---|
Net income 2024 * | -269M -25.27M | Net income 2025 * | 125M 11.74M | EV / Sales 2024 * | 25.6 x |
Net cash position 2024 * | 341M 32.07M | Net cash position 2025 * | 226M 21.2M | EV / Sales 2025 * | 3.61 x |
P/E ratio 2024 * |
-8.55
x | P/E ratio 2025 * |
13.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.24% |
Latest transcript on PledPharma AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 17-06-15 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 17-12-30 |
Chief Tech/Sci/R&D Officer | - | 22-05-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mats Blom
CHM | Chairman | 59 | 21-03-31 |
Director/Board Member | 50 | 19-12-31 | |
Thomas Lönngren
BRD | Director/Board Member | 73 | 21-03-31 |
1st Jan change | Capi. | |
---|---|---|
+9.58% | 115B | |
+12.41% | 107B | |
-12.38% | 22.31B | |
-3.46% | 21.6B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B | |
-24.50% | 8.28B |